Sanofi's sleeping sickness drug wins FDA OK and a lucrative priority review voucher too

The FDA on Tuesday approved the first oral treatment for sleeping sickness (human African trypanosomiasis) from Sanofi and the Drugs for Neglected Diseases initiative, and provided the partners with a priority review voucher that they may sell for about $100 million.